Department of Biosciences, Laboratory for Analytical Toxicology, Novum Research Park, Karolinska Institutet, SE-141 83 Huddinge, Sweden.
Mutagenesis. 2010 Sep;25(5):499-504. doi: 10.1093/mutage/geq033. Epub 2010 Jun 15.
Colon cancer is a multistage process where adenomatous polyps developing in a normal mucosa may further progress to neoplasia. DNA adducts are biomarkers linked to exposure to carcinogenic compounds, tumour formation and clinically observed cancer. Such DNA adducts have been detected in the mucosa of colon cancer patients. The aim of this study was to investigate whether there are differences in DNA adduct levels and patterns in mucosa from patients with colon cancer, polyps and non-cancerous controls and whether some DNA adducts could be markers for colon cancer development. Human colonic biopsies were collected from healthy controls (n = 10), polyp patients (n = 22) (from both normal and polyp tissue) and colon cancer patients (n = 32) (from both tumour tissue and adjacent normal mucosa). In 150 tissues specimens (when small amount of tissue, the same type of tissues were pooled from each patient), DNA adduct levels and patterns were analysed by the (32)P-high-performance liquid chromatography method. There were no significant difference in the total levels of DNA adducts between any of the groups. Levels of two single DNA adducts were decreased in mucosa adjacent to tumours as compared to mucosa from healthy controls. One DNA adduct was found only in tumour tissue and adjacent mucosa from the colon cancer patients. A food derived, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-related DNA adduct was detected in 106 of the 150 tissues analysed, but in similar levels in tissues from controls, polyp patients or cancer patients. In conclusion, three individual DNA adducts may be interesting candidates for further evaluation of their possible role as biomarkers in human carcinogenesis. Furthermore, a food-derived PhIP-related adduct contributes to the general DNA adduct pattern in most individuals, indicating a minor role of this adduct in human colon carcinogenesis.
结肠癌是一个多阶段的过程,正常黏膜中出现的腺瘤性息肉可能会进一步发展为肿瘤。DNA 加合物是与致癌化合物暴露、肿瘤形成和临床观察到的癌症相关的生物标志物。已经在结肠癌患者的黏膜中检测到这种 DNA 加合物。本研究旨在探讨结肠癌患者、息肉患者和非癌症对照者的黏膜中 DNA 加合物水平和模式是否存在差异,以及某些 DNA 加合物是否可以作为结肠癌发展的标志物。从健康对照者(n = 10)、息肉患者(n = 22)(来自正常和息肉组织)和结肠癌患者(n = 32)(来自肿瘤组织和相邻正常黏膜)中收集人类结肠活检。在 150 个组织标本(当组织量少时,从每个患者的相同类型的组织中汇集)中,通过(32)P-高效液相色谱法分析 DNA 加合物水平和模式。任何一组之间的 DNA 加合物总水平均无显著差异。与健康对照者的黏膜相比,肿瘤相邻黏膜中两种单个 DNA 加合物的水平降低。一种 DNA 加合物仅在结肠癌患者的肿瘤组织和相邻黏膜中发现。一种来源于食物的 2-氨基-1-甲基-6-苯基咪唑[4,5-b]吡啶(PhIP)相关的 DNA 加合物在分析的 150 个组织中的 106 个中被检测到,但在对照者、息肉患者或癌症患者的组织中水平相似。总之,三种个体 DNA 加合物可能是作为人类致癌作用中生物标志物的进一步评估的有趣候选物。此外,一种来源于食物的 PhIP 相关加合物对大多数个体的一般 DNA 加合物模式有贡献,表明该加合物在人类结肠癌发生中的作用较小。